Search Results 141-150 of 17292 for hba1c

  1. Study Evaluating The Safety And Efficacy Of Semaglutide, And The Fixed-Dose Combination Of Cilofexor And Firsocostat, Alone And In Combination, In Participants With Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

    - HbA1c ≤ 10%; - INR ≤ 1.4, unless due to therapeutic anticoagulation; - Platelet count ≥ 125,000/uL; - Alanine Aminotransferase (ALT) < 5 x ULN; - Serum ...

  2. Randomized Global Phase 3 Study to Evaluate the Impact of Obeticholic Acid Treatment on Nonalcoholic Steatohepatitis Patients - Mayo Clinic

    HbA1c > 9.5%. Total bilirubin > 1.5 mg/dL. Evidence of other known forms of known chronic liver disease such as alcoholic liver disease, hepatitis B ...

  3. A Study to Evaluate Proinsulin and Glucagon Secretion in Postpartum Women with and without Gestational Diabetes - Mayo Clinic

    Women with an HbA1c of ≥ 5.7% (39mmol/mol) in early pregnancy or a history of diabetes. Prior therapy with an anti-diabetic medication, or a medication ...

  4. A Trial To Investigate Long Term Effectiveness And Safety Of Lonapegsomatropin In Adults With Growth Hormone Deficiency - Mayo Clinic

    Poorly controlled diabetes, defined as HbA1C higher than 7.5% according to central laboratory at Visit 6 in trial TCH-306; 2. Use of diabetes mellitus drugs ...

  5. Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III - Mayo Clinic

    Poorly controlled diabetes mellitus (HbA1c >10%),; Current or within 1 month use of any form of corticosteroids,; Severe asthma that is poorly controlled on ...

  6. Mediterranean Diet Post-liver Transplantation - Mayo Clinic

    - Uncontrolled diabetes mellitus (HbA1c > 10%) - Associated medical conditions incompatible with safe participation in a nutritional intervention study ...

  7. A Study Of Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Bladder Cancer - Mayo Clinic

    Uncontrolled diabetes is defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c 7–<8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise ...

  8. Emricasan, A Caspase Inhibitor, For Treatment Of Subjects With Decompensated NASH Cirrhosis - Mayo Clinic

    Uncontrolled diabetes mellitus (HbA1c >9%). Change in diabetes medications or vitamin E within 3 months of screening. Restrictive bariatric surgery or ...

  9. A Study to Evaluate Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery - Mayo Clinic

    In subjects with medical history of diabetes, medical documentation of postoperative remission of diabetes mellitus (fasting glucose < 110 mg/dL), and HbA1c ...

  10. A Study Of MGL-3196 (Resmetirom) In Patients With MASH Who Have Undergone Liver Transplant For MASH Cirrhosis Or Other Etiologies - Mayo Clinic

    Fasting serum glucose ≥5.6 mmol/L (100 mg/dL) OR 2 hr post-load glucose levels ≥7.8 mmol/L (≥140 mg dL) OR glycated hemoglobin (HbA1c) ≥5.7% (39 mmol/L) ...